Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00983255 · ClinicalTrials.gov registry record · Phase 1
Ascending Dose Pharmacokinetic (PK) and Absolute Bioavailability (BA)
A Phase 1 study, sponsored by Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
- Completed
- Registry status
- Phase 1
- Development phase
- 90
- Enrollment target
NCT00983255 is a Phase 1 study that has completed, run by Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). The registered enrollment target is 90 participants.
The verdict
NCT00983255, a Phase 1 study, has completed, sponsored by Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 90 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of single rising and multiple rising IV doses of TR-701 FA and to determine the absolute bioavailability of oral TR-701 FA following single oral and IV dose administrations in healthy adult subjects.
Interventions
- DRUG TR-701 FA for injection, 200 mg/vial
- DRUG TR-701 FA tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2009-09 |
| Est. Completion | 2010-01 |
| Phase | Phase 1 |
Sponsor
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)18 total trials
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00983255
The ClinicalTrials.gov registry entry for NCT00983255 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which TR-701 FA for injection, 200 mg/vial is the first listed.
NCT00983255 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00983255 about?
NCT00983255 is a clinical study titled "Ascending Dose Pharmacokinetic (PK) and Absolute Bioavailability (BA)". The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of single rising and multiple rising IV doses of TR-701 FA and to determine the absolute bioavailability of oral TR-701 FA following single oral and IV dose administrations in healthy adult subjects.
What is the current status of trial NCT00983255?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 90 participants. The study started on 2009-09. Estimated completion is 2010-01.
What interventions are being tested in trial NCT00983255?
The interventions under investigation include: TR-701 FA for injection, 200 mg/vial (DRUG), TR-701 FA tablets (DRUG).
Who is sponsoring clinical trial NCT00983255?
This trial is sponsored by Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.